Literature DB >> 15041721

Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus.

Katerina Dvorakova1, Claire M Payne, Lois Ramsey, Hana Holubec, Richard Sampliner, Jessica Dominguez, Bohuslav Dvorak, Harris Bernstein, Carol Bernstein, Anil Prasad, Ronnie Fass, Haiyan Cui, Harinder Garewal.   

Abstract

PURPOSE: Barrett's esophagus (BE) is a common premalignant lesion of the distal part of the esophagus that arises as a consequence of chronic duodenogastroesophageal reflux. Interleukin (IL)-6 is a pleiotropic cytokine that regulates immune defense mechanisms and hematopoiesis. In addition, IL-6 may also be involved in malignant transformation and tumor progression. IL-6 has been shown to inhibit apoptosis. The major aim of this study was to evaluate expression of IL-6 in BE at the protein and mRNA levels. In addition, we tested whether proteins that are associated with IL-6 signaling, phosphorylated signal transducer and activator of transcription 3 and two antiapoptotic proteins, Bcl-x(L) and Mcl-1, are also expressed in the same tissues. EXPERIMENTAL
DESIGN: Biopsies of duodenum, BE, and squamous epithelium were evaluated by using a human cytokine protein array, ELISA, real-time PCR, and immunohistochemistry.
RESULTS: Increased IL-6 levels were found to be secreted from BE tissue compared with duodenum or squamous epithelium from sites adjacent or 5 cm away from the BE lesion. IL-6 mRNA was also elevated in BE compared with duodenum or squamous epithelium in five of seven patients. Immunohistochemical studies confirmed IL-6 expression in intestinal glandular epithelium in BE tissue. Activated signal transducer and activator of transcription 3, Mcl-1, and Bcl-x(L) are present at higher levels in BE glands, with lower levels being found in duodenum or squamous epithelium
CONCLUSIONS: These data, taken together, suggest that elevated IL-6 levels in BE may contribute to the development of apoptosis resistance, thereby placing this epithelium at higher risk of developing malignancy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15041721     DOI: 10.1158/1078-0432.ccr-0437-03

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  34 in total

1.  The decreased expression of Beclin-1 correlates with progression to esophageal adenocarcinoma: the role of deoxycholic acid.

Authors:  Heather B Roesly; Mohammad R Khan; Hwu Dau Rw Chen; Kimberly A Hill; Nirushan Narendran; George S Watts; Xiaoxin Chen; Katerina Dvorak
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-02-02       Impact factor: 4.052

2.  Contribution of Fibroblast and Mast Cell (Afferent) and Tumor (Efferent) IL-6 Effects within the Tumor Microenvironment.

Authors:  Honor J Hugo; Stephanie Lebret; Eva Tomaskovic-Crook; Nuzhat Ahmed; Tony Blick; Donald F Newgreen; Erik W Thompson; M Leigh Ackland
Journal:  Cancer Microenviron       Date:  2012-02-08

3.  Inflammation and cancer.

Authors:  Noemí Eiró; Francisco J Vizoso
Journal:  World J Gastrointest Surg       Date:  2012-03-27

4.  A novel mechanism of acid and bile acid-induced DNA damage involving Na+/H+ exchanger: implication for Barrett's oesophagus.

Authors:  Aaron Goldman; Mohammad Shahidullah; David Goldman; Ludmila Khailova; George Watts; Nicholas Delamere; Katerina Dvorak
Journal:  Gut       Date:  2010-09-28       Impact factor: 23.059

5.  Diallyl Disulfide Suppresses the Inflammation and Apoptosis Resistance Induced by DCA Through ROS and the NF-κB Signaling Pathway in Human Barrett's Epithelial Cells.

Authors:  Cheng Feng; Yumei Luo; Yuanyuan Nian; Dong Liu; Xiaoran Yin; Jing Wu; Jia Di; Rong Zhang; Jun Zhang
Journal:  Inflammation       Date:  2017-06       Impact factor: 4.092

6.  miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus.

Authors:  Cameron M Smith; David I Watson; Mary P Leong; George C Mayne; Michael Z Michael; Bas P L Wijnhoven; Damian J Hussey
Journal:  World J Gastroenterol       Date:  2011-02-28       Impact factor: 5.742

7.  Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Katerina Dvorak; George S Watts; Lois Ramsey; Hana Holubec; Claire M Payne; Carol Bernstein; Gareth J Jenkins; Richard E Sampliner; Anil Prasad; Harinder S Garewal; Harris Bernstein
Journal:  Am J Gastroenterol       Date:  2009-01-27       Impact factor: 10.864

8.  Adiponectin modulates DCA-induced inflammation via the ROS/NF-κ B signaling pathway in esophageal adenocarcinoma cells.

Authors:  Rong Zhang; Xiaoran Yin; Haitao Shi; Jie Wu; Pramod Shakya; Dong Liu; Jun Zhang
Journal:  Dig Dis Sci       Date:  2013-10-05       Impact factor: 3.199

Review 9.  Role of interleukin-6 in Barrett's esophagus pathogenesis.

Authors:  Katerina Dvorak; Bohuslav Dvorak
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

10.  Exercise and the Prevention of Oesophageal Cancer (EPOC) study protocol: a randomized controlled trial of exercise versus stretching in males with Barrett's oesophagus.

Authors:  Brooke M Winzer; Jennifer D Paratz; Marina M Reeves; David C Whiteman
Journal:  BMC Cancer       Date:  2010-06-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.